BenevolentAI lead atopic dermatitis drug misses the mark

[cafead]

via BenevolentAI has reported disappointing results in a phase 2 trial of lead drug BEN-2293 in atopic dermatitis (AD), as the drug was unable to show the hoped-for effect on symptoms, even though it was safe and well-tolerated.

article source